Appili Therapeutics
Presence
Appili Therapeutics is a company listed under the stock ticker APLI (CA).
Acquisition, funding and merger involving Appili Therapeutics.
- Aditxt has announced the acquisition of Appili Therapeutics (posted on April 3 2024).
Executives
View the org chart displaying its 11 main executives
Most searched biographies at Appili Therapeutics
- Don Cilla, Director, President and Chief Executive Officer
- Juergen Froehlich, Director
- Armand Balboni, Chairman of the Board
Popular executive movements at Appili Therapeutics
- Prakash Gowd has joined the company as Director (posted on November 14 2023).
Create your alert
to follow the executive moves at Appili Therapeutics.
Biotechnology
Appili Therapeutics has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Appili Therapeutics
- News 2024 - Appili Therapeutics
- Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
- Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
- Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
- Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
- Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
- Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
- News 2023 | Appili - LIVE
- Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
- Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
- View more press releases Close
Social media about Appili Therapeutics
- Appili Therapeutics on Wikipedia, Google News & Yahoo Finance
- Appili Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Don Cilla 
Call Appili Therapeutics at +1 902...
